In this setting, as opposed to the non-diabetic or I/R scenario, the effects of liraglutide on cardiac function were no
different from placebo. Noyan-Ashraff et al. studied the effects of liraglutide in the post-MI setting, reporting reductions in mortality, improved cardiac function, and increased expression of cardioprotective genes in non-diabetic mice.44 A separate study included in the same paper reported improved mortality in diabetic mice that received liraglutide, whereas mice treated with metformin, despite showing an equivalent improvement in glycaemia, did not show the same improvement in mortality. However, in contrast with non-diabetic mice, the effects of liraglutide on cardiac function and downstream signaling in diabetic mice were not reported.